AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05435872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Artificial intelligence Cloud Platform
Description: The Artificial intelligence Cloud Platform would be used as the auxiliary device for endoscopists during the whole endoscopic examination to help endoscopists complete the quality control, indicate potential lesions, and aid in diagnosis.
Study NCT06534307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: metabolic examination
Description: metabolic development using blood analysis including blood components, metabolic parameters (Glucose, HbA1c, cholestrol)
Study NCT06534307 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire Reynolds Intellectual Assessment Scales and Screening
Description: The RIAS is standardized intelligence test. The RIAS provides an Total Intelligence Index (GIX, estimate of the general intelligence/g-factor), Verbal Intelligence Index (VIX) and the Nonverbal Intelligence Index (NIX). Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better cognitive performance.
Study NCT06534307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: electroencephalogram
Description: neurocognitive development
Study NCT06534307 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Movement Assessment Battery for Children
Description: The M-ABC-2 is an standardized test to assess the motoric development. Adding up subscores addressing manual dexterity, aiming and catching, and balance delivers a total score of the motoric performance.~Test scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean better performance.
Study NCT06534307 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Continuous Performance Test
Description: The CPT measures selective attention, sustained attention as well as impulsive behavior. Checklist scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean worse performance.
Study NCT06534307 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Diagnostic System for Mental Disorders
Description: The FBB-ADHS assesses a total score for ADHD-like behavior and subscores for the symptom trias of ADHD (attention deficit, motoric hyperactivity as well as impulsive behavior, Questionnaire scores are reported on a T-scale. Range of T-scale from scores 20 to 100 (average performance between scores 40 and 60). Higher scores mean higher amount of symptoms.
Study NCT06534307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: kidney function tests
Description: urine examination (proteomics, cytokines, lipidomics)
Study NCT06534307 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Five to Fifteen
Description: The FTF 5-15R is a questionnaire to evaluate the child's developmental outcome in different areas of everyday life (cognition, language, and motor impairment as well as social, emotional, and behavioral problems). Individual item scores are added up per area and divided by the number of items. This results in a common scale value. Range of Percentile scores from 0 to 100 (0-90: no developmental problem; 90 and higher: hint for developmental problem). Higher scores mean worse developmental outcome.
Study NCT06534307 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiovacular examination
Description: measurement of pulse wave velocity
Study NCT06057051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent Infinite
Description: iStent Infinite Trabecular Micro-Bypass System
Study NCT06326372 — intervention group
Intervention type: PROCEDURE
Intervention: control
Description: Fraction of inspired oxygen (FiO2) is titrated guided by oxygen saturation in that range; %95\<oxygen saturation
Study NCT06326372 — intervention group
Intervention type: PROCEDURE
Intervention: ORi+SpO2
Description: Titration of fraction of inspired oxygen (FiO2) guided by ORI and oxygen saturation FiO2 will be titrated by reducing 10% if Ori>0.01 and oxygen saturation ≥ 98% until Ori is 0.00.~FiO2 will not be changed if Ori is 0.00 and %95\<oxygen saturation≤%98 FiO2 will be increased by 10% if oxygen saturation \<95 or PaO2\<60 mmHg
Study NCT06149260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector
Description: Inject semaglutide subcutaneously once weekly, on the same day each week, at any time of day, in a dose increasing mode: the initial dose of 0.25mg QW (once a week), increased to 0.5mg QW after 4 weeks, and then maintained 0.5mg until the end of treatment in total 24 weeks.
Study NCT05209893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Application based video home exercise for the knee osteoarthritis
Study NCT05209893 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper Based Rehabilitation
Description: Paper instruction based home exercise for the knee osteoarthritis
Study NCT05940285 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic 99mTc-Tetrofosmin CZT-SPECT
Description: Patients included in the study will undergo subsequently at 1-month after acute coronary syndrome Dynamic 99mTc-Tetrofosmin CZT-SPECT followed by FFR and IMR assessment
Study NCT05343871 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinovac
Description: Sinovac inactivated COVID-19 vaccine:~● Full dose (0.5 ml)
Study NCT05343871 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD1222
Description: AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine:~* Full dose (0.5 ml)~* Half dose (0.25 ml)
Study NCT05343871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: AstraZeneca ChAdOx1-S recombinant AZD1222 vaccine:~* Full dose (0.5 ml)~* Half dose (0.25 ml)
Study NCT05343871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Pfizer/BioNTech BNT162b2 mRNA vaccine:~* Full dose (30 micrograms)~* Half dose (15 micrograms)~* One-third dose (10 micrograms)
Study NCT05343871 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2
Description: Pfizer/BioNTech BNT162b2 mRNA vaccine:~* Full dose (30 micrograms)~* Half dose (15 micrograms)~* One-third dose (10 micrograms)
Study NCT05718765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACES intervention
Description: The exercise perception intervention program is divided into three stage, and every four weeks is a stage. The theme of the first stage is to make the patient have the intention to exercise. The theme of the second stage is to provide effective support for the patient, so that the patient can take the initiative to start exercise. The theme of the third stage is to enable patients to keep exercising.~The exercise intervention is a 12-week progressive intradialytic combined cycling exercise which proceed in the first HD 2 hours for safety. Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE.
Study NCT05718765 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care with sham intervention
Description: Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 hemodialysis hours.
Study NCT05662501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pleioflow-RF
Description: Subjects who are going to undergo scheduled cardiac surgery and are prone to developing renal insufficiency, will receive the Pleioflow-RF device in conjunction with IABP during CPB. Subjects will be followed until 30-days post-intervention.
Study NCT05895214 — intervention group
Intervention type: PROCEDURE
Intervention: oncological relevance of the mesopancreas
Description: Invasion status Invasion depth in mm Depth of mesopancreas in mm Treitz fascia intact (histopathological examination)
Study NCT06146543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress ball
Description: Before the procedure begins, the patient's free hand will be given an elastic ball that is large enough to hold in the palm of the hand and squeeze easily. He/she will be asked to squeeze this ball slowly throughout the process. At the end of the procedure, the ball will be removed from his hand and the patient will be relieved.
Study NCT04954365 — intervention group
Intervention type: DRUG
Intervention: Rescue Post-Operative Nausea and Vomiting (PONV) treatment according to the standard of care (SOC)
Description: Rescue Post-Operative Nausea and Vomiting (PONV) treatment
Study NCT04954365 — intervention group
Intervention type: DRUG
Intervention: Amisulpride
Description: Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
Study NCT06542731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: Specified dose on specified days
Study NCT06542731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days
Study NCT06542731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Specified dose on specified days
Study NCT06542731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Specified dose on specified days
Study NCT06004401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonopazan +Amoxicillin
Description: Vonopazan 20mg 2//day+Amoxicillin
Study NCT06004401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole +colloidal pectin bismuth +Amoxicillin +Clarithromycin
Description: Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Amoxicillin 1g 2/day+Clarithromycin 500mg 2/day
Study NCT06004401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonopazan +Minocycline
Description: Vonopazan 20mg 2/day+Minocycline 100mg 2/day
Study NCT06004401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole +colloidal pectin bismuth +Metronidazole +Clarithromycin
Description: Rabeprazole tablets 10mg 2/day+colloidal pectin bismuth 200mg 2/day+Metronidazole 0.4g 3/day+Clarithromycin 500mg 2/day
Study NCT04373057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharide
Description: GOS will be administered at determined dose levels per protocol once daily from about 30 days before transplant to about 4 weeks after transplant.
Study NCT02847949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGN002
Description: IGN002 is a monoclonal antibody fusion protein
Study NCT04373057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin will be administered at comparable dose level as GOS (in Phase II) once daily from about 30 days before transplant to about 4 weeks after transplant.
Study NCT05953935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OKTO
Description: Static Monopolar Capacitive Resistive Resistive Radiofrequency Equipment at 448 kHz
Study NCT05953935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard clinical procedures
Description: standard clinical procedures
Study NCT05953051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with bone/PrP-composite
Description: During standard ACL reconstruction, the drilled bone debris is collected in a sterile filtered chamber.~Then the bone debris is mixed with PrP. After fixation of the graft the composite is inserted into the drilled tunnel at the interface between tendon to bone. The intraarticular aperture sites are sealed by use of fibrin that is previously gathered out of the PrP as well.
Study NCT05953051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction (Standard)
Description: Standard ACL reconstruction with Semitendinosus alone or plus gracilis, femoral fixation via extracortical fixation by adjustable loop device, tibial fixation via a bio-interference screw or adjustable device
Study NCT05747261 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-004, dose 1
Description: Adeno-associated viral vector carrying the SMN gene single infusion at dose 1. The duration of the infusion is about 60 minutes.
Study NCT05747261 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-004, dose 2
Description: Adeno-associated viral vector carrying the SMN gene single infusion at dose 2. The duration of the infusion is about 60 minutes.
Study NCT05616195 — intervention group
Intervention type: OTHER
Intervention: 3D printed bone prosthesis replacement surgery
Description: To report the postoperative complications and limb function of patients who underwent 3D-printed bone prosthesis replacement in Henan Cancer Hospital.
Study NCT05747261 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-004, dose 3
Description: Adeno-associated viral vector carrying the SMN gene single infusion at dose 3. The duration of the infusion is about 60 minutes.
Study NCT04898283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10,000 MG01 +10,000 T521
Description: Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
Study NCT04898283 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30,000 MG01 +10,000 T521
Description: Purified allergen extract polymerized with glutaraldehyde, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupressaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections.
Study NCT04898283 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous
Description: The same solution and presentation as the active treatment, but without active ingredients
Study NCT04614519 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: Insufflation pressure at 12mmHg and conventional instrumentation
Study NCT05552092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal temperature monitoring according to the depth
Description: Core temperatures will be measured with a tympanic thermometer as a reference. When the tympanic membrane (TM) temperature is constant after measuring three consecutive times at 10 seconds intervals, the temperature will be assumed as the core body temperature.~Initially, the esophageal stethoscope (ES) will be inserted to a depth of 45 cm from the incisor. After 30 minutes of monitoring, when the changes in the body temperatures stabilized, initial temperatures of the TM and ES thermistor will be assessed.~After 5 minutes, ES will be taken out 2 cm back, and the temperatures of each site will be measured when the temperature change of the ES thermistor stabilized below 0.1°C. Eventually, the depth of ES will be changed from 45 to 27 cm with a 2 cm interval, and the temperature at each position will be measured.
Study NCT05552092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anatomical landmark
Description: For the further evaluation of the optimal insertion depth of GDT, anatomical landmarks such as distance from the cricoid cartilage to the carina (CCD) and distance from the carina to the intervertebral disc between T8 and T9 (CDD) will be measured using an electronic caliper on a preoperative chest X-ray.
Study NCT06566508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide Intracanal medication
Description: Calcium Hydroxide Intracanal medication
Study NCT06566508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leddermix Intracanal medication
Description: Leddermix Intracanal medication
Study NCT06566508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asiaticoside Intracanal medication
Description: Asiaticoside Intracanal medication
Study NCT06417723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary nerve block
Description: It is aimed to reach the maxillary nerve trace with a peripheral nerve block needle using the suprazigomatic approach and to create a temporary block in the maxillary nerve with local anaesthetic injection.
Study NCT06526923 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SP-101 and doxorubicin Cohort 1
Description: Single inhaled dose of SP-101 and doxorubicin Dose 1
Study NCT06526923 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SP-101 and doxorubicin Cohort 2
Description: Single inhaled dose of SP-101 and doxorubicin Dose 2
Study NCT04594200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A&F)
Description: In this protocol, we propose comparing 2 intervention design elements in a multifactorial design. Specifically, we will evaluate:~i) an emphasis on antibiotic-associated harms in comparison to messages that focus on lack of benefit; ii) simple versus adjusted peer comparators to represent a target for the prescribing quality indicators~We will also investigate the effects of the inclusion of materials developed by Choosing Wisely Canada (CWC) - namely the viral prescription pad - to help physicians act upon the feedback to reduce their prescribing
Study NCT05180526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLETLI
Description: 80 mg was given subcutaneously at week 1, followed by 40 mg of Glorio (adamuzumab injection) every other week from week 1 to week 22 (12 doses).
Study NCT05454293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Talk at a Time: Race
Description: This intervention consists of short videos that include didactic modules and social modeling for having conversations with children about race, ethnicity, culture, and discrimination. The total intervention takes approximately 1.5-2 hours to complete online, and parents can move through the videos at their own pace.
Study NCT05454293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One Talk at a Time: General
Description: This intervention consists of short videos that include modules and handouts with tips for parent-child communication strategies for navigating difficult topics, such as dating and current events.
Study NCT04815603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGE-117
Description: Active Treatment
Study NCT04815603 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05734482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: for subcutaneous injection only
Study NCT05734482 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: for subcutaneous injection only
Study NCT04911543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-JNJ-70099731
Description: \[18F\]JNJ-70099731 injection will be administered intravenously.
Study NCT04218019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTFields
Description: The NovoTTF-200 A device used in this trial delivers very low intensity, alternating electric fields to the tumor site through the scalp. These fields are known as Tumor Treating Fields or TTFields.
Study NCT06202807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06202807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study NCT06202807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Including：~1. Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~2. Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~3. Pulmonary function training, including standing training, cough training, and diaphragm muscle training.